Cable One (CABO) Q1 2025 Earnings Call May 01, 2025 05:00 PM ET Company Participants Jordan Morkert - VP - Investor RelationsJulie Laulis - Chair, President & Chief Executive OfficerTodd Koetje - Chief Financial OfficerFrank Louthan - Managing Director Conference Call Participants Sebastiano Petti - Senior Research AnalystBrandon Nispel - Director & Equity Research Analyst Operator Thank you for standing by. My name is Rebecca, and I will be your conference operator today. At this time, I would like to welc ...

Velocity Financial (VEL) Q1 2025 Earnings Call May 01, 2025 05:00 PM ET Company Participants Christopher Oltmann - Treasurer & Director of Investor RelationsChristopher Farrar - Co-Founder, CEO & DirectorMark Szczepaniak - Chief Financial OfficerEric Hagen - Managing Director Conference Call Participants Don Fandetti - AnalystSteven Delaney - Analyst Operator Good day, and welcome to Velocity Financial Inc. First Quarter twenty twenty five Conference Call. All participants will be in listen only mode. After ...

Envista (NVST) Q1 2025 Earnings Call May 01, 2025 05:00 PM ET Company Participants Jim Gustafson - VP - IRPaul Keel - CEOEric Hammes - Chief Financial OfficerJonathan Block - Managing Director Conference Call Participants Jason Bednar - Senior Research AnalystElizabeth Anderson - Senior Managing Director & Research AnalystJeffrey Johnson - Managing Director, Senior Research AnalystAllen Lutz - Senior Equity Research AnalystSteven Valiquette - MD & Senior Equity Research Analyst - Covering Health Care Techno ...

Financial Data and Key Metrics Changes - In the first quarter, the company delivered 1,200,000 total results to patients, with core revenue growing by 11% and non-GAAP operating expenses increasing by only 4%, leading to a more than 60% increase in adjusted EBITDA [6][11][12] - Screening revenue exceeded guidance, increasing by 14% to $540 million, while Precision Oncology revenue grew by 4% to $167 million on a core basis [11][12] - Adjusted EBITDA increased by 61% to $63 million, with adjusted EBITDA margin expanding by 280 basis points [12][18] Business Line Data and Key Metrics Changes - Cologuard growth was driven by rescreens, CareGAP programs, and new ordering providers, with rescreens now accounting for over 25% of total Cologuard orders [11][55] - The CareGAP program grew triple digits last year and is expected to continue strong double-digit growth this year [9][12] - The launch of Cologuard Plus is anticipated to deliver increased value, improved performance, and higher adoption rates [10][19] Market Data and Key Metrics Changes - Customer engagement by the field force increased by over 30% year over year, with more than 190,000 providers ordering during the first quarter, marking a nearly 10% increase year over year [16][32] - The company ended the quarter with cash and securities of $786 million, reflecting a $249 million convertible note paydown [14] Company Strategy and Development Direction - The company is focused on enhancing its commercial execution, with a purpose-built commercial organization and expanded field team engaging providers at record rates [6][8] - The launch of Cologuard Plus is positioned to revolutionize colorectal cancer screening, with a focus on making it the first option in healthcare provider screening toolkits [19][20] - The company is also advancing its precision oncology portfolio with the launch of OncoDetect, aimed at benefiting six million cancer patients [21][22] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the strong start in 2025, highlighting the successful launch of two innovative products and the positive impact of commercial improvements [25] - The company expects continued revenue growth, with total revenue guidance increased to between $3.07 billion and $3.12 billion for the year [14][15] - Management noted that they are on track to generate meaningful free cash flow growth through productivity and working capital initiatives [13][14] Other Important Information - The company has taken actions to optimize costs, expecting annual savings of $18 million, with $9 million coming in 2025 [13] - The launch of CancerGuard is planned for the second half of 2025, enabling population-level screening for cancer [24] Q&A Session Summary Question: Focus on commercial execution and changes made - Management highlighted that the volume of calls by sales representatives is up, with a 10% increase in per-rep productivity, indicating an engaged sales force [30][32] Question: Guidance unpacking and revenue outlook - Management indicated that the increased guidance is primarily due to improvements in commercial execution, with expectations of 13% growth in the first half and 15% in the second half of the year [40] Question: Sales and marketing investments - Management acknowledged higher sales and marketing expenses but emphasized that revenue growth significantly outpaced these investments, indicating effective leverage [45] Question: Rescreens contribution to total volume - Management confirmed that rescreens are a significant growth driver and could contribute a couple of points to overall volume this year [56] Question: Blood testing pipeline and timeline - Management expressed confidence in the timeline for blood testing developments, with a readout expected in midsummer [68][79] Question: Cologuard Plus traction and mix - Management reported that Cologuard Plus is currently available for Medicare Part B patients, with expectations for growth as more payers contract for coverage [82][85] Question: Commercial payer discussions and pricing for CancerGuard - Management indicated positive discussions with payers regarding Cologuard Plus and noted that pricing for CancerGuard has not yet been finalized [90]

Procore (PCOR) Q1 2025 Earnings Call May 01, 2025 05:00 PM ET Company Participants Alexandra Geller - Head of IRTooey Courtemanche - Founder, President, CEO & Chairperson of the BoardHoward Fu - Chief Financial OfficerSaket Kalia - Managing DirectorMatthew Martino - Vice PresidentAdam Borg - Managing Director - Equity Research Conference Call Participants Dylan Becker - Research AnalystJoe Vruwink - Senior Research AnalystBrent Bracelin - Sr. Research AnalystDavid Hynes - Managing Director, Software Lead An ...

Roku (ROKU) Q1 2025 Earnings Call May 01, 2025 05:00 PM ET Company Participants Conrad Grodd - Vice President, Investor RelationsCory Carpenter - Internet Equity ResearchAnthony Wood - Founder, Chairman & CEODan Jedda - Chief Financial OfficerCharlie Collier - President of Roku MediaJustin Patterson - Managing DirectorMustafa Ozgen - President - Devices, Products & TechnologyJames Heaney - SVP - Equity Research Conference Call Participants Brent Navon - AnalystVasily Karasyov - Founder & Senior AnalystLaura ...

Lumen Technologies (LUMN) Q1 2025 Earnings Call May 01, 2025 05:00 PM ET Company Participants Jim Breen - Senior VP - IRKate Johnson - President and CEOChris Stansbury - EVP and CFONick Del Deo - Managing DirectorFrank Louthan - Managing Director Conference Call Participants Michael Rollins - AnalystBatya Levi - Managing Director - Communications, Media & Infrastructure AnalystJim Schneider - Senior Equity AnalystGregory Williams - AnalystJonathan Chaplin - Lead Analyst Operator Greetings, and welcome to th ...

Workiva (WK) Q1 2025 Earnings Call May 01, 2025 05:00 PM ET Company Participants Katie White - Senior Director - IRJulie Iskow - President and Chief Executive OfficerJill Klindt - Executive VP & CFOPatrick Schulz - Vice President & Senior Research AssociateRyan Krieger - VP - Software Equity ResearchDominique Manansala - Equity Research AssociateBrett Huff - Managing DirectorJohn Messina - Research Associate Conference Call Participants Steve Enders - AnalystJake Roberge - Equity Research AnalystAdam Hotchk ...

Universal Display (OLED) Q1 2025 Earnings Call May 01, 2025 05:00 PM ET Company Participants Darice Liu - Senior Director of Investor Relations & Corporate CommunicationsSteven Abramson - President, Chief Executive Officer & DirectorBrian Millard - VP, CFO & TreasurerTyler Bisset - Equity Research Associate Conference Call Participants James Ricchiuti - Senior AnalystMehdi Hosseini - Senior Equity Research AnalystScott Searle - Managing Director, Senior Research AnalystNam Hyung Kim - Senior AnalystNone - A ...

LeMaitre Vascular (LMAT) Q1 2025 Earnings Call May 01, 2025 05:00 PM ET Company Participants Dorian LeBlanc - CFOGeorge LeMaitre - Chairman & CEOShaymus Contorno - Equity Research AssociateDavid Roberts - President & DirectorMichael Petusky - Managing DirectorRick Wise - Managing Director - Medical Technology & SuppliesDaniel Stauder - Director - Equity Research Conference Call Participants Michael Sarcone - AnalystFrank Takkinen - Senior Research AnalystJim Sidoti - AnalystBrett Fishbin - Vice President & ...